CR20190179A - Anticuerpos anti-il-33 y usos de estos - Google Patents

Anticuerpos anti-il-33 y usos de estos

Info

Publication number
CR20190179A
CR20190179A CR20190179A CR20190179A CR20190179A CR 20190179 A CR20190179 A CR 20190179A CR 20190179 A CR20190179 A CR 20190179A CR 20190179 A CR20190179 A CR 20190179A CR 20190179 A CR20190179 A CR 20190179A
Authority
CR
Costa Rica
Prior art keywords
antibodies
anticuerpos
para
los
dermatitis
Prior art date
Application number
CR20190179A
Other languages
English (en)
Inventor
Robert Jan Benschop
Chetankumar Natvarlal Patel
Stephanie Marie Truhlar
Julian Davies
Angela Jeannine Okragly
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20190179A publication Critical patent/CR20190179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CR20190179A 2016-10-28 2017-10-24 Anticuerpos anti-il-33 y usos de estos CR20190179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414258P 2016-10-28 2016-10-28
PCT/US2017/058020 WO2018081075A1 (en) 2016-10-28 2017-10-24 Anti-il-33 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20190179A true CR20190179A (es) 2019-08-26

Family

ID=60263117

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190179A CR20190179A (es) 2016-10-28 2017-10-24 Anticuerpos anti-il-33 y usos de estos

Country Status (37)

Country Link
US (2) US10501536B2 (es)
EP (1) EP3532499B1 (es)
JP (1) JP6830533B2 (es)
KR (1) KR102266144B1 (es)
CN (1) CN109863173B (es)
AR (1) AR109948A1 (es)
AU (1) AU2017351183B2 (es)
BR (1) BR112019005139A2 (es)
CA (1) CA3039232C (es)
CL (1) CL2019001043A1 (es)
CO (1) CO2019003047A2 (es)
CR (1) CR20190179A (es)
CY (1) CY1124360T1 (es)
DK (1) DK3532499T3 (es)
EA (1) EA201990778A1 (es)
EC (1) ECSP19029758A (es)
ES (1) ES2878037T3 (es)
HR (1) HRP20211221T1 (es)
HU (1) HUE055621T2 (es)
IL (1) IL265689B2 (es)
JO (1) JOP20190093A1 (es)
LT (1) LT3532499T (es)
MA (1) MA46619B1 (es)
MD (1) MD3532499T2 (es)
MX (1) MX394799B (es)
PE (1) PE20191045A1 (es)
PH (1) PH12019500929A1 (es)
PL (1) PL3532499T3 (es)
PT (1) PT3532499T (es)
RS (1) RS62120B1 (es)
SI (1) SI3532499T1 (es)
SM (1) SMT202100442T1 (es)
TN (1) TN2019000086A1 (es)
TW (2) TWI647238B (es)
UA (1) UA121293C2 (es)
WO (1) WO2018081075A1 (es)
ZA (1) ZA201901935B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
EP4055044A1 (en) 2019-11-04 2022-09-14 MedImmune Limited Anti il-33 therapeutic agent for treating renal disorders
WO2021089563A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
CN113214395A (zh) * 2020-01-21 2021-08-06 迈威(上海)生物科技股份有限公司 抗st2抗体及其应用
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN115315527A (zh) 2020-03-13 2022-11-08 免疫医疗有限公司 用于治疗il33中存在风险等位基因的受试者的治疗方法
WO2021204707A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
BR112022022620A2 (pt) 2020-05-11 2022-12-20 Medimmune Ltd Formulações de anticorpos anti-il-33
CN111620948B (zh) * 2020-06-10 2022-04-08 南京赛新生物科技有限公司 针对il-33的抗体
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
EP4573121A1 (en) 2022-08-19 2025-06-25 MedImmune Limited Method of selecting patients for treatment with an il-33 axis antagonist
AR134489A1 (es) * 2023-11-27 2026-01-21 Glaxosmithkline Ip Dev Ltd Proteinas de unión a antígeno
WO2025120567A1 (en) 2023-12-07 2025-06-12 Medimmune Limited Method of treatment of asthma
WO2025210099A1 (en) 2024-04-04 2025-10-09 Medimmune Limited Method of treatment and selecting a subject
WO2025242618A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Bronchiectasis treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CA2685124A1 (en) 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin Products for altering il-33 activity and methods therefor
EP2069784A4 (en) 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
KR102003075B1 (ko) * 2011-02-23 2019-07-23 에프. 호프만-라 로슈 아게 인간 il33r에 대한 항체 및 이의 용도
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9758578B2 (en) * 2013-12-26 2017-09-12 Mitsubishi Tanabe Pharma Corporation Human anti-IL-33 neutralizing monoclonal antibody
EP3092253B1 (en) * 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
CA2946511C (en) * 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
MY190209A (en) 2015-03-31 2022-04-05 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
EP3402521A4 (en) 2016-01-14 2019-11-20 AnaptysBio, Inc. INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها

Also Published As

Publication number Publication date
US20200048340A1 (en) 2020-02-13
US10501536B2 (en) 2019-12-10
KR20190054160A (ko) 2019-05-21
RS62120B1 (sr) 2021-08-31
BR112019005139A2 (pt) 2019-06-04
JP2019534282A (ja) 2019-11-28
ECSP19029758A (es) 2019-05-31
CA3039232A1 (en) 2018-05-03
PT3532499T (pt) 2021-07-05
TW201829459A (zh) 2018-08-16
CN109863173A (zh) 2019-06-07
EP3532499B1 (en) 2021-05-05
MD3532499T2 (ro) 2021-09-30
US10913793B2 (en) 2021-02-09
AU2017351183A1 (en) 2019-04-11
ES2878037T3 (es) 2021-11-18
PH12019500929A1 (en) 2019-12-02
EP3532499A1 (en) 2019-09-04
DK3532499T3 (da) 2021-06-28
JP6830533B2 (ja) 2021-02-17
TN2019000086A1 (en) 2020-07-15
EA201990778A1 (ru) 2019-09-30
PL3532499T3 (pl) 2021-11-08
CL2019001043A1 (es) 2019-08-30
MX2019004863A (es) 2019-08-12
US20180118821A1 (en) 2018-05-03
AU2017351183B2 (en) 2020-04-09
MX394799B (es) 2025-03-24
PE20191045A1 (es) 2019-08-06
CO2019003047A2 (es) 2019-04-12
SMT202100442T1 (it) 2021-09-14
HUE055621T2 (hu) 2021-12-28
AR109948A1 (es) 2019-02-06
CA3039232C (en) 2021-05-25
CN109863173B (zh) 2022-06-03
IL265689B2 (en) 2024-02-01
TW201920675A (zh) 2019-06-01
TWI676680B (zh) 2019-11-11
CY1124360T1 (el) 2022-07-22
SI3532499T1 (sl) 2021-08-31
TWI647238B (zh) 2019-01-11
HRP20211221T1 (hr) 2021-10-29
LT3532499T (lt) 2021-08-10
WO2018081075A1 (en) 2018-05-03
ZA201901935B (en) 2020-11-25
KR102266144B1 (ko) 2021-06-18
IL265689A (en) 2019-05-30
UA121293C2 (uk) 2020-04-27
JOP20190093A1 (ar) 2019-04-25
MA46619B1 (fr) 2021-09-30
IL265689B1 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
CR20190179A (es) Anticuerpos anti-il-33 y usos de estos
CY1126255T1 (el) Χρησεις ανταγωνιστων il-13 για την αγωγη της ατοπικης δερματιτιδας
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
MX2015010599A (es) Anticuerpos dirigidos contra il-33 y sus usos.
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CO2017002719A2 (es) Anticuerpos anti-glucagón
CR20170203A (es) Moleculas de unión a antígeno biespecíficas activadoras de células t
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2019012756A2 (es) Anticuerpos agonistas contra btla y sus usos
CL2018002340A1 (es) Anticuerpos para il-17c
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2024005680A (es) Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
MX2019002673A (es) Composiciones y metodos para tratar demencia.
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
AR129996A2 (es) Anticuerpos dirigidos contra il-33 y sus usos
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
CR20190176A (es) Usos de antagonistas de il-13 para el tratamiento de dermatitis atópica
AR095235A1 (es) Anticuerpos dirigidos contra il-33 y sus usos